tirzepatide nash phase 3 for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis Pharmacotherapy for Non-alcoholic Fatty Liver

As a dual-action therapy, it targets both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, delivering a comprehensive approach to appetite control, weight loss, and blood sugar regulation

What the clinical research actually shows Three categories of evidence exist regarding semaglutide and blood clots: randomized controlled trials, real-world observational studies, and individual case reports

It is marketed under the brand names Wegovy, approved for weight management, and Ozempic, approved for type 2 diabetes management

Improved Metabolic Health Patients on tirzepatide often observe better blood sugar levels, lower blood pressure, improved cholesterol profiles, and decreased inflammation markers